NCT03854903: WI231696: ASPIRE Bosutinib

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be progressive on at least 1 aromatase inhibitor & 1 CDK 4/6 inhibitor
Exclusions: Patients with active uncontrolled or symptomatic brain metastases- see trial for details; Patients that have received more than 3 lines of chemotherapy

Comments are closed.

Up ↑